Fig. 2: IT LNPs that functionally deliver mRNA to human tumor cells in vivo.
From: Nanoparticle delivery of a prodrug-activating bacterial enzyme leads to anti-tumor responses
a Enrichment in the top 12% of LNPs screened, subdivided by the type of cholesterol, helper lipid, and stereopure ionizable lipid (n = 4 experimental replicates, mean +/− SD). Data analyzed by two-tailed unpaired student’s t-test. b LNP28 and LNPIT were identified from the screen based on enrichment of the stereopure ionizable lipids and other components. c When injected intratumorally, both IT LNPs functionally delivered NanoLuc mRNA to the tumors as demonstrated by the quantification of bioluminescence via IVIS (n = 3-4 experimental replicates, mean +/− SD). Data analyzed by ordinary one-way ANOVA. d IT LNPs functionally delivered a second reporter mRNA tested, aVHH, to CD47+ human head and neck FaDu cancer cells and various infiltrating immune cells in the tumors, as quantified via flow cytometry (n = 3 experimental replicates, mean +/− SD). Data analyzed by two-way ANOVA with Tukey post-hoc test for multiple comparisons. (ECs: endothelial cells). We found that IT LNPIT and IT LNP28 functionally delivered two different reporter mRNA molecules to FaDu tumor cell types in vivo. Source data are provided as a Source Data file.
